% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Heinrich:301581,
      author       = {M. C. Heinrich and J.-Y. Blay and H. Gelderblom and S.
                      George and P. Schöffski and M. von Mehren and J. R.
                      Zalcberg and R. L. Jones and Y.-K. Kang and A. A. Razak and
                      J. Trent and S. Attia and A. Le Cesne and K. Boye and D.
                      Goldstein and C. Sánchez and B. L. Siontis and P. Cox and
                      E. Davis and M. L. Sherman and R. Ruiz-Soto and S.
                      Bauer$^*$},
      title        = {{U}pdated {O}verall {S}urvival and {L}ong-{T}erm {S}afety
                      {W}ith {R}ipretinib {V}ersus {S}unitinib in {P}atients
                      {W}ith {GI} {S}tromal {T}umor: {F}inal {O}verall {S}urvival
                      {A}nalysis {F}rom {INTRIGUE}.},
      journal      = {Journal of clinical oncology},
      volume       = {43},
      number       = {20},
      issn         = {0732-183X},
      address      = {Alexandria, Va.},
      publisher    = {American Society of Clinical Oncology},
      reportid     = {DKFZ-2025-01089},
      pages        = {2239-2244},
      year         = {2025},
      note         = {2025 Jul 10;43(20):2239-2244},
      abstract     = {In the INTRIGUE phase III trial (ClinicalTrials.gov
                      identifier: NCT03673501), adult patients with advanced
                      gastrointestinal stromal tumor previously treated with
                      imatinib were randomly assigned 1:1 to ripretinib 150 mg
                      once daily or sunitinib 50 mg once daily (4 weeks on/2 weeks
                      off). In the primary analysis, overall survival (OS) was
                      immature. In this study, we report the final planned
                      analysis of OS (key secondary end point), progression-free
                      survival (PFS) on third-line therapy (second PFS;
                      prespecified exploratory end point), and long-term safety.
                      Final OS analysis was prespecified to occur with
                      approximately 200 and ≥145 events in the overall and KIT
                      exon 11 intention-to-treat (ITT) populations, respectively.
                      As of March 15, 2023, there were 211 and 151 OS events in
                      the overall ITT and KIT exon 11 ITT populations,
                      respectively. Median OS was similar between second-line
                      ripretinib and sunitinib in both populations (overall, 35.5
                      v 31.5 months; KIT exon 11, 35.5 v 32.8 months). Median
                      second PFS (on third-line therapy) for the overall ITT
                      population was similar between the ripretinib and sunitinib
                      arms (7.7 v 7.4 months). Safety was consistent with the
                      primary analysis. OS from this analysis was similar between
                      arms, and second PFS suggests that receiving ripretinib did
                      not adversely affect the PFS of third-line therapy.},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40408605},
      doi          = {10.1200/JCO-24-02818},
      url          = {https://inrepo02.dkfz.de/record/301581},
}